Cancer drug Avastin tops forecast for 2014's top-selling drugs worldwide
Blockbusters Lipitor and Plavix disappear from list due to patent expirations
It’s not the most expensive drug, but according to consensus sales forecasts from financial analysts compiled by Thomson Reuters, Roche’s cancer drug Avastin will secure the spot for the world’s top-selling drug in 2014, with a forecasted $8.9B in sales. Roche dominates the list with three drugs—joining Avastin are cancer drugs Rituxan and Herceptin.
World’s Top-Selling Drugs in 2014
1. Avastin (Roche), $8.9B - cancer
2. Humira (Abbott), $8.5B - arthritis
3. Enbrel (Pfizer/Amgen), $8B - arthritis
4. Crestor (AstraZeneca), $7.7B - cholesterol
5. Remicade (Merck/J&J), $7.6B - arthritis
6. Rituxan (Roche), $7.4B - cancer
7. Lantus (Sanofi-Aventis), $7.1B - diabetes
8. Advair (GlaxoSmithKline), $6.8B - asthma/COPD
9. Herceptin (Roche), $6.4B - cancer
10. NovoLog (Novo Nordisk), $5.7B - diabetes
Topping the 2010 forecast, also compiled by Reuters, is Pfizer’s Lipitor, with an estimated $11.7B in sales. The cholesterol drug was the seventh most prescribed drug in the US in 2009, according to IMS Health.
Sanofi-Aventis and Bristol Myers Squibb’s Plavix snagged second place on Reuters’ 2010 list of top sellers, with an estimated $9.6B in sales. The anticlotting agent, along with Lipitor and Novartis’ blood pressure medication Diovan, are the only three that appear on the 2010 list but not on the 2014 list. The patents for Lipitor and Plavix expire next year, while the patent for Diovan expires in 2012.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
